IL314916A - Bispecific CD28 antibodies for targeted T cell activation - Google Patents
Bispecific CD28 antibodies for targeted T cell activationInfo
- Publication number
- IL314916A IL314916A IL314916A IL31491624A IL314916A IL 314916 A IL314916 A IL 314916A IL 314916 A IL314916 A IL 314916A IL 31491624 A IL31491624 A IL 31491624A IL 314916 A IL314916 A IL 314916A
- Authority
- IL
- Israel
- Prior art keywords
- targeted
- cell activation
- bispecific antibodies
- bispecific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317491P | 2022-03-07 | 2022-03-07 | |
| US202263323893P | 2022-03-25 | 2022-03-25 | |
| PCT/IB2023/000124 WO2023170474A1 (en) | 2022-03-07 | 2023-03-07 | Cd28 bispecific antibodies for targeted t cell activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314916A true IL314916A (en) | 2024-10-01 |
Family
ID=86272440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314916A IL314916A (en) | 2022-03-07 | 2023-03-07 | Bispecific CD28 antibodies for targeted T cell activation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240002544A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4490192A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508066A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119233993A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023232992A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249273A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314916A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023170474A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024512574A (ja) * | 2021-03-22 | 2024-03-19 | ノビミューン エスアー | Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| AU2023362569A1 (en) * | 2022-10-21 | 2025-04-24 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| WO2025051895A1 (en) * | 2023-09-06 | 2025-03-13 | Novimmune Sa | Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity |
| TW202544034A (zh) * | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至cd28及nectin-4之雙特異性抗體 |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| WO2006050949A2 (de) | 2004-11-11 | 2006-05-18 | Tegenero Ag | Superagonistische anti-cd28 antikörper |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN110437337B (zh) | 2013-02-26 | 2024-07-30 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
| US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
| US11260117B2 (en) * | 2017-05-26 | 2022-03-01 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
| WO2019016411A1 (en) * | 2017-07-21 | 2019-01-24 | Novimmune Sa | GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE |
| CN112566938B (zh) * | 2018-06-03 | 2025-04-01 | 拉姆卡普生物测试有限公司 | 针对ceacam5和cd47的双特异性抗体 |
| CN119143875A (zh) | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| KR20210104836A (ko) | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
| WO2020132024A1 (en) | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
| US20200223925A1 (en) | 2018-12-21 | 2020-07-16 | Hoffmann-La Roche Inc. | Tumor-targeted superagonistic cd28 antigen binding molecules |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| AU2020350205A1 (en) | 2019-09-18 | 2022-05-12 | Lamkap Bio Alpha AG | Bispecific antibodies against CEACAM5 and CD3 |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| CR20220627A (es) | 2020-06-23 | 2023-02-17 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se derigen a her2 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| KR20230121772A (ko) * | 2020-12-18 | 2023-08-21 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이적 항체 |
-
2023
- 2023-03-07 EP EP23720353.4A patent/EP4490192A1/en active Pending
- 2023-03-07 CN CN202380039111.0A patent/CN119233993A/zh active Pending
- 2023-03-07 AU AU2023232992A patent/AU2023232992A1/en active Pending
- 2023-03-07 US US18/180,116 patent/US20240002544A1/en active Pending
- 2023-03-07 IL IL314916A patent/IL314916A/en unknown
- 2023-03-07 WO PCT/IB2023/000124 patent/WO2023170474A1/en not_active Ceased
- 2023-03-07 JP JP2024553409A patent/JP2025508066A/ja active Pending
- 2023-03-07 CA CA3249273A patent/CA3249273A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3249273A1 (en) | 2023-09-14 |
| US20240002544A1 (en) | 2024-01-04 |
| WO2023170474A1 (en) | 2023-09-14 |
| AU2023232992A1 (en) | 2024-08-15 |
| EP4490192A1 (en) | 2025-01-15 |
| JP2025508066A (ja) | 2025-03-21 |
| CN119233993A (zh) | 2024-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276975A (en) | Chimeric antigen receptor cell immunotherapy with a bispecific antibody | |
| IL286536A (en) | Multispecific egfr x cd28 antibodies | |
| IL320152A (en) | Bispecific antibodies against PD-L1 and CD28 for immune checkpoint-dependent T cell activation | |
| IL291186A (en) | Bispecific antibody chimeric antigen receptor cell immunotherapy | |
| WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| EP4410965A4 (en) | T LYMPHOCYTE PRODUCTION PROCESS | |
| IL288965A (en) | A method for generating a multivalent bispecific antibody-expressing cell using a targeted combination of multiple expression cassettes in a defined organization | |
| PT4157876T (pt) | Anticorpos anti-pd-1 | |
| IL288967A (en) | A method for generating a bispecific bivalent antibody-expressing cell using a targeted combination of multiple expression cassettes in a defined organization | |
| CA3258462A1 (en) | VARIANT ANTIBODIES THAT BIND TO GAMMA-DELTA T LYMPHOCYTE RECEPTORS | |
| CA3261147A1 (en) | DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES | |
| EP4048700A4 (en) | BISPECIFIC ANTI-BCMA/ANTI-4-1BB ANTIBODIES AND THEIR USES | |
| IL321509A (en) | CD28/OX40 bispecific antibodies | |
| IL319891A (en) | Anti-CD28 antibodies | |
| CA3260186A1 (en) | Formulations for Bispecific Antibodies: Anti-PD-L1/Anti-4-1BB | |
| WO2014132131A3 (en) | In situ affinity maturation of antibodies | |
| CA3271184A1 (en) | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation | |
| HK40131732A (zh) | Cd28/ox40双特异性抗体 | |
| CA3277184A1 (en) | Cd28/ox40 bispecific antibodies | |
| IL315451A (en) | Methods for the purification of bispecific antibodies | |
| HK40116564A (en) | Methods for purifying bispecific antibodies | |
| HK40082085A (en) | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies | |
| IL320411A (en) | ANTI-CD3 antibodies | |
| HK40101272A (en) | Antibodies that bind gamma-delta t cell receptors | |
| CA3289016A1 (en) | Anti-cd28 x anti-trop2 antibodies |